Crizotinib: A new treatment option for ALK-positive non-small cell lung cancer;crizotinib: Una nueva opción de tratamiento para cáncer pulmonar de célula no pequeña ALK positivo

Annals of Pharmacotherapy

Volumn 47, Issue 2, 2013, Pages 189-197

  O'Bryant, Cindy L ^a   Wenger, Sarah D ^a   Kim, Miryoung ^a   Thompson, Lisa A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; MIDAZOLAM;

ANAPLASTIC LYMPHOMA KINASE GENE; ANOREXIA; AREA UNDER THE CURVE; BLURRED VISION; BRADYCARDIA; CONSTIPATION; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EDEMA; ESOPHAGITIS; ESOPHAGUS DISEASE; FATIGUE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GENE; HUMAN; KIDNEY CYST; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOPHOBIA; PHOTOPSIA; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT PLANNING; VISUAL IMPAIRMENT; VITREOUS FLOATERS; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84873974299     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R002     Document Type: Review

References (37)

1. Dimou A, Harrington K, Syrigos KN. From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell. lung cancer. Patholog Res Int 2011;2011:312346.
2. SEER Cancer Statistics Review, 1973-2008. Washington, DC: US National Institutes of Health. National Cancer Institute.
3. Pearson R, Kolesar JM. Targeted therapy for NSCLC: ALK inhibition. J Oncol Pharm Pract 2012;18:271-4.
4. Gadgeel SM, Bepler G. Crizotinib: an anaplastic lymphoma kinase inhibitor. Future Oncol 2011;7:947-53.
5. Kwak E, Bang Y, Camidge R, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
6. Product information. Xalkori (crizotinib). New York, NY: Pfizer Inc., February 2012. www.pfizerpro.com/hcp/xalkori_home (accessed 2012 Dec 1).
7. Gaughan E, Costa D. Genotype-driven therapies for non-small-cell-lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol 2011;3:113-25.
8. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011;17:2081-6.
9. Weickhardt AJ, Camidge DR. The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. Clin Invest 2011;1:1119-26.
10. Sasaki T, Janne PA. New strategies for treatment of ALK rearranged nonsmall cell lung cancers. Clin Cancer Res 2011;17:7213-8.
11. Cui J, Tran-Dube M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011;54:6342-63.
12. Li C, Alvey C, Bello A, et al. Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol 2011;29(suppl):e13065.
13. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29: e443-5.
14. Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009;27(15 suppl):3509.
15. Curran MP. Crizotinib in locally advanced or metastatic non-small cell lung cancer. Drugs 2012;72:99-107.
16. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003, published date: August 9, 2006. http://ctep.cancer.gov (accessed 2012 Dec 1).
17. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
18. Camidge DR, Bang YJ, Kwak E, et al. Activity and safety of crizotinib in patients with ALK-positive non-small lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-9.
19. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12:1004-12.
20. Kim DW, Ahn MJ, Shi Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small lung cancer (NSCLC). J Clin Oncol 2012;30(suppl):7533.
21. Shaw AT, Kim DW, Nakagawa K, et al. Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small lung cancer (NSCLC) (PROFILE 1007). Ann Oncol 2012;23(suppl 9):LBA1_PR.
22. CinicalTrials. gov. www.Clinicaltrials.gov (accessed 2012 Dec 1).
23. Food and Drug Administration, Department of Health and Human Services. NDA 202570 accelerated approval letter. www.accessdata.fda.gov/ drugsatfda_docs/appletter/2011/202570s000ltr.pdf (accessed 2012 Dec 1).
24. Camidge, DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangement potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16:5581-90.
25. Husain H, Rudin CM. ALK-targeted therapy for lung cancer: ready for primetime. Oncology 2011;25:597-601.
26. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66.
27. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer. V.3.2012 www.nccn. org (accessed 2012 Dec 1).
28. Hanna N, Shepard FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer prevoiusly treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
29. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy naïve patients with advanced stage non-small cell lung cancer. J Clin Oncol 2008;26:3543-51.
30. Arnold M. Diagnostic costs could hamper Xalkori's potential. Med Market Media 2011;46:8.
31. Pillai RN, Ramalingam SS. The biology and clinical features of nonsmall cell lung cancers with EML4-ALK translocation. Curr Oncol Rep 2012;14:105-10.
32. Milkiewicz K, Ott G. Inhibitors of anaplastic lymphoma kinase: a patent review. Expert Opin Ther Patents 2010;20:1653-81.
33. Webb T, Slavish J, George R, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small molecule inhibitor development for therapy. Expert Rev Anticancer Ther 2009;9:331-56.
34. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010;363:1727-33.
35. Tanizaki J, Okamoto I, Okamoto K, et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in nonsmall cell lung cancer according to MET alterations. J Thorac Oncol 2011;6:1624-31.
36. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29: 4803-10.
37. Chi AS, Batchelor TT, Kwak EL, et al. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol 2012; 30:e30-3.